Mizuho Securities Reaffirm Bullish Stance on Surgery Partners (SGRY)

Surgery Partners (NASDAQ:SGRY) is one of the most promising mid-cap healthcare stocks under $50.

On December 18, Mizuho Securities analyst Ann Hynes reiterated her Buy rating on Surgery Partners (NASDAQ:SGRY) stock. She has assigned a price target of $19, which leads to an upside of 21% from the current trading level.

Hynes’s bullish rating is backed by a positive 2026 forecast for managed care and health facilities. She highlighted that the managed care space is at the tail end of a three-year negative underwriting cycle and sees the coming year as a turning point. According to Hynes, 2026 could set the tone for improved margins in the coming years, especially across Medicaid and Medicare. Such expected commercial turnaround within managed care makes her highly optimistic about Surgery Partners (NASDAQ:SGRY) stock.

As of December 19, Surgery Partners (NASDAQ:SGRY) stock has received coverage from 11 analysts. Eight of them have assigned a Buy rating to the stock, while three have given a Hold rating. The stock offers an estimated 67.5% upside potential from current levels, and has a consensus target price of $26.30.

Surgery Partners (NASDAQ:SGRY) delivers surgical and ancillary services across different locations within the United States. Through single- and multi-specialty facilities, they offer services such as physician practices, anesthesia, and urgent care. The company also focuses on non-emergency surgical procedures, including orthopedics, ophthalmology, and pain management.

While we acknowledge the potential of SGRY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT:  Cathie Wood’s Stock Portfolio: Top 10 Stocks to Buy and 30 Most Fantastic Stocks Every Investor Should Pay Attention To.

Disclosure: None. This article is originally published at Insider Monkey.